Oxford BioDynamics PLC - biotechnology company developing precision medicine tests based on the EpiSwitch 3D genomics platform - Reports that Vulpes Testudo Fund, controlled by Non-Executive Director Stephen Diggle has sold 777,000 shares of one pence each at an average price of 38.3p each. Diggle is now interested in 27.6 million shares in total, through the Vulpes Testudo and Vulpes Life Sciences Funds. These represent approximately 13.62% of Oxford BioDynamics’s current issued share capital. Company’s market capitalisation is £69.79 million.

Current stock price: 34.50 pence, up 1.5%

12-month change: up 70%

Copyright 2023 Alliance News Ltd. All Rights Reserved.